A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants With Major Depressive Disorder Who Experience a Loss of Interest and Pleasure
| Condition | Depressive Disorder, Major, Anhedonia |
|---|---|
| Phase | Phase 3 |
| Sponsor | Janssen Research & Development, LLC |
| Status | Terminated |
| Enrollment | 47 participants |
| Interventions | Aticaprant |
| Start date | Sep 19, 2024 |
| Completion date | Apr 9, 2025 |
| Results posted | Jun 8, 2026 |
Summary
The purpose of this study is to assess how well aticaprant works compared to placebo when given in addition to antidepressant therapy (selective serotonin reuptake inhibitor \[SSRI\] or serotonin-norepinephrine reuptake inhibitor \[SNRI\]) in preventing return of depression symptoms in participants with major depressive disorder who experience a loss of interest and pleasure and who achieve a stable response after treatment with adjunctive aticaprant.
Time From Randomization Into Double Blind (DB) Treatment Maintenance Phase to the First Documentation of Relapse
| DB Treatment Maintenance Phase: Aticaprant 10 mg | NA days |
|---|
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- CBT+ for Depression — University of Wisconsin, Madison
- Probing the Dorsolateral Prefrontal Cortex and Central Executive Network for Improving Neu — Stanford University
- Severe Asthma, MepolizumaB and Affect: SAMBA Study — University Hospital Southampton NHS Foundation Trust
- Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for — Levomecor Inc.
- A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major De — Levomecor Inc.
- Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders — Massachusetts General Hospital